Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 16370 | Other Identifier | Sterling IRB Protocol ID |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Meisch Temple Massager, Inc | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The goal of this observational study is to learn how the Temple Massager System affects stress, emotional wellbeing, sleep, and quality of life in women aged 35 to 65.
The Temple Massager System is a non-electric, drug-free hand-held device used for self-massage of the temple area. The system also includes a body lotion and an optional lavender aromatherapy. It is sold as a general wellness product.
The main questions this study aims to answer are:
Does daily use of the Temple Massager System lower self-reported stress and improve emotional wellbeing over 4 weeks? Does daily use improve self-reported sleep quality and overall quality of life?
This is a single-arm observational study. There is no placebo or comparison group. Researchers will compare how participants feel before they start using the device to how they feel after 4 weeks of daily use.
Participants will:
Receive a Temple Massager System at no cost Complete a 1-week baseline period before using the device Use the device once a day for at least 5 minutes for 4 weeks Answer short daily questions about device use, headaches, and over-the-counter medication use Complete weekly check-in surveys about stress, mood, and sleep Complete longer surveys at the start and end of the study Keep the device after the study ends
The study runs for 5 weeks per participant and takes place entirely from home through a secure app-based platform. No clinic visits are required.
The Temple Massager System is a non-electric, drug-free, hand-held massage device intended for self-massage of the area around the temples. The system includes:
The Temple Massager device with multiple attachment heads A body lotion containing mango butter, shea butter, arnica, and St. John's Wort An optional lavender essential oil for aromatherapy
The Temple Massager is sold as a general wellness product. It is not a medical device. About 70 to 80 percent of buyers are women.
Over 15 years of real-world use, the device has been used by combat veterans, police officers, 911 dispatchers, and healthcare workers. Many have reported benefits including lower tension, reduced stress, improved sleep, and fewer headaches. This study formalizes those personal accounts into structured, IRB-governed research.
Study Design This is a single-arm, open-label, observational study. There is no placebo group and no comparison group. The study is decentralized, meaning participants take part from home and never visit a clinic. All data is collected through a secure, HIPAA-compliant, app-based study platform.
The study enrolls 48 women aged 35 to 65 with a target of 40 participants completing all study activities.
Study Structure
Each participant moves through the following periods:
Screening and Enrollment (up to 2 weeks): Participants confirm eligibility, give electronic informed consent, and provide shipping information.
Shipping (up to 2 weeks): The participant receives the Temple Massager System at home.
Baseline Week (Week 0, Days 1 to 7): Participants do not use the device yet. They complete starting-point surveys and begin a daily log of headaches and any over-the-counter medication use. This week sets a baseline for comparison.
Active Use Period (Weeks 1 to 4, Days 8 to 35): Participants use the device once a day for at least 5 minutes, targeting the temple area. Each day they complete a short log covering device use, headaches, and medication use.
End-of-Study Assessments (Days 35 to 38): Participants complete the same starting-point surveys again, plus a satisfaction survey.
The total study duration is 5 weeks per participant. Participants keep the device after the study and receive a $25 gift card for completing end-of-study assessments.
Measures Used
The study uses validated, widely used self-report tools:
Generalized Anxiety Disorder 7-item Scale (GAD-7): Used in this study as a measure of emotional wellbeing and subclinical stress symptoms. Not used as a diagnostic tool.
PROMIS Sleep Disturbance Short Form 8a: Measures sleep quality. PROMIS-29 Profile v2.1: Measures quality of life across 7 areas including physical function, emotional wellbeing, fatigue, sleep, pain interference, and social participation.
Weekly pulse measures: GAD-2 and PHQ-2 short scales, plus visual rating scales for stress and sleep quality.
Daily logs: device use, headache occurrence and intensity, and over-the-counter medication use.
Aromatherapy Sensitivity Note About 10 to 15 percent of people are sensitive to lavender oil. All participants will perform a small patch test on the inner wrist before first using the aromatherapy component. Anyone who experiences irritation will stop the aromatherapy and continue with just the device and lotion. Lavender sensitivity does not exclude participants from the study.
Primary Outcome Change in GAD-7 total score from baseline (Day 1) to end-of-study (Day 35). Why This Study Few self-administered wellness products have been studied through structured, IRB-reviewed research. Findings from this study will contribute knowledge about the real-world effects of regular massage device use on stress, emotional wellbeing, sleep, and quality of life, and will help inform the design of future research.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Temple Massager System Users | Women aged 35 to 65 who use the Temple Massager System once daily for at least 5 minutes over a 4-week active intervention period, following a 1-week baseline observation period with no device use. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Temple Massager System | Device | A non-electric, drug-free, hand-held mechanical massage wellness device used for self-massage of the temple region. The system includes the device with multiple attachment heads, a body lotion containing mango butter, shea butter, arnica, and St. John's Wort, and an optional lavender essential oil aromatherapy component. Participants use the device once daily for at least 5 minutes over a 4-week active intervention period. The Temple Massager System is a commercially available general wellness product. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Generalized Anxiety Disorder 7-item Scale (GAD-7) Total Score | The GAD-7 is a 7-item self-report questionnaire measuring emotional wellbeing on a 4-point Likert scale (0-3) per item with a 2-week recall window. Total score range: 0 to 21. Higher scores indicate greater symptom severity (worse outcome). In this study, the GAD-7 is used as a measure of subclinical emotional wellbeing, not as a diagnostic tool. | Baseline (Day 1) to End-of-Study (Day 35) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in PROMIS Sleep Disturbance Short Form 8a T-Score | The PROMIS Sleep Disturbance Short Form 8a is an 8-item NIH-developed self-report instrument measuring sleep disturbance over the past 7 days. Scored using T-score methodology with a population mean of 50 and standard deviation of 10. T-score range typically 30 to 80. Higher T-scores indicate greater sleep disturbance (worse outcome). | Baseline (Day 1) to End-of-Study (Day 35) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Generalized Anxiety Disorder 2-item Scale (GAD-2) Score | The GAD-2 is a 2-item self-report screening instrument for anxiety symptoms, scored on a 4-point Likert scale (0-3) per item. Total score range: 0 to 6. Higher scores indicate greater symptom severity (worse outcome). Administered as a weekly pulse measure. | Weekly at Weeks 0 through 4 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Women aged 35 to 65 who experience daily stress, anxiety, tension headaches, facial tension, or TMJ-related discomfort, with self-reported headache frequency of two or more per week. Participants must be in good general health, on stable medication regimens if applicable, able to use a personal smartphone or tablet, and willing to use the Temple Massager System daily for 4 weeks. Participants are recruited nationwide through wellness research participant pools, social media advertising, and targeted digital outreach to women in wellness communities.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Megan L Morris, CNC | Contact | 415-320-0000 | contact@moqcollective.com |
| Name | Affiliation | Role |
|---|---|---|
| Colleen Quinn | MOQ Collective, Ltd | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| MOQ Collective, Ltd. | Fairfax | California | 94930 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 22250775 | Background | Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, Johnston KL, Pilkonis PA. Development of short forms from the PROMIS sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011 Dec 28;10(1):6-24. doi: 10.1080/15402002.2012.636266. | |
| 20685078 | Background | Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, Amtmann D, Bode R, Buysse D, Choi S, Cook K, Devellis R, DeWalt D, Fries JF, Gershon R, Hahn EA, Lai JS, Pilkonis P, Revicki D, Rose M, Weinfurt K, Hays R; PROMIS Cooperative Group. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol. 2010 Nov;63(11):1179-94. doi: 10.1016/j.jclinepi.2010.04.011. Epub 2010 Aug 4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018781 | Tension-Type Headache |
| D007319 | Sleep Initiation and Maintenance Disorders |
| ID | Term |
|---|---|
| D051270 | Headache Disorders, Primary |
| D020773 | Headache Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Change in PROMIS-29 Profile v2.1 Domain T-Scores | The PROMIS-29 Profile v2.1 is a 29-item NIH-developed self-report instrument measuring quality of life across 7 domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and social participation. Each domain produces a T-score with a population mean of 50 and standard deviation of 10. For physical function and social participation domains, higher T-scores indicate better outcomes; for symptom domains (anxiety, depression, fatigue, sleep disturbance, pain interference), higher T-scores indicate worse outcomes. | Baseline (Day 1) to End-of-Study (Day 35) |
| Change in Weekly Over-the-Counter Rescue Medication Frequency | Self-reported weekly frequency of over-the-counter pain medication use, measured as count of medication days per week (range 0 to 7 days). Lower frequency indicates a better outcome. Comparison made between the baseline week (Week 0) and the final week of the active intervention period (Week 4). | Baseline Week (Week 0) and Final Active Week (Week 4) |
| Change in Patient Health Questionnaire 2-item Scale (PHQ-2) Score | The PHQ-2 is a 2-item self-report screening instrument for depression symptoms, scored on a 4-point Likert scale (0-3) per item. Total score range: 0 to 6. Higher scores indicate greater symptom severity (worse outcome). Administered as a weekly pulse measure. | Weekly at Weeks 0 through 4 |
| Change in Self-Reported Stress Visual Analogue Scale (VAS) Score | Self-reported stress level measured using a Visual Analogue Scale ranging from 0 (no stress) to 10 (extreme stress). Higher scores indicate greater stress (worse outcome). Administered as a weekly pulse measure. | Weekly at Weeks 0 through 4 |
| Change in Self-Reported Sleep Quality Visual Analogue Scale (VAS) Score | Self-reported sleep quality measured using a Visual Analogue Scale ranging from 0 (worst sleep quality) to 10 (best sleep quality). Higher scores indicate better sleep quality (better outcome). Administered as a weekly pulse measure. | Weekly at Weeks 0 through 4 |
| Net Promoter Score (NPS) for the Temple Massager System | Single-item self-report measure of participant willingness to recommend the Temple Massager System to others, scored on a scale of 0 (not at all likely) to 10 (extremely likely). Higher scores indicate greater satisfaction (better outcome). | End-of-Study (Day 35) |
| 16717171 | Background | Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. |
| D009422 | Nervous System Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D001523 | Mental Disorders |